Article
Oncology
Asahiro Morishita, Joji Tani, Takako Nomura, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Tingting Shi, Hiroki Yamana, Takanori Matsui, Tadayuki Takata, Takayuki Sanomura, Yoshihiro Nishiyama, Takashi Himoto, Tetsu Tomonari, Akio Moriya, Tomonori Senoo, Koichi Takaguchi, Tsutomu Masaki
Summary: Recent studies have shown that the combination therapy of DEB-TACE followed by cTACE may be more effective for intermediate stage HCC patients, with a significantly higher complete response rate in the cTACE group. The total tumor number was the only factor that increased the complete response rate in the cTACE group, and the overall survival rate of complete response patients was higher than non-complete response patients in the cTACE group. Adverse events in the cTACE group were limited, with only one case of severe thrombocytopenia out of twenty-seven patients.
Article
Oncology
Thomas J. Vogl, Maximilian Lahrsow
Summary: Liver metastases of colorectal cancer are a significant issue, and surgery and systemic chemotherapy are common treatment options. When conventional therapies fail or metastases recur, interventional radiologists can offer local therapies such as transarterial chemoembolization. These treatments can be combined with other local or systemic therapies.
Article
Oncology
Yonghua Bi, Yang Wang, Wenguang Zhang, Huibin Lu, Jianzhuang Ren, Xinwei Han
Summary: The study aimed to report the preliminary outcomes of drug-eluting beads TACE loaded with raltitrexed in patients with unresectable or recurrent HCC. The results showed that this treatment regimen had good efficacy and safety, and could be considered as an effective palliative therapy for patients with unresectable or recurrent HCC.
Article
Biology
Su Min Cho, Hee Ho Chu, Jong Woo Kim, Jin Hyung Kim, Dong Il Gwon
Summary: DEB-TACE using HepaSpheres 20-40 μm can serve as a safe and effective initial treatment for patients with HCC > 5 cm. Subsequent Cis-TACE acts as a good adjuvant method to enhance tumor response following initial DEB-TACE.
Article
Oncology
Bin Chai, Dongqiao Xiang, Wei Wang, Yanqiao Ren, Fuquan Wang, Jihua Wang, Guofeng Zhou, Chuansheng Zheng
Summary: This retrospective study investigated the relationship between arterial enhancement fraction (AEF) and treatment response and survival in hepatocellular carcinoma (HCC) patients treated with drug-eluting bead TACE. The results showed that changes in AEF were correlated with the response of HCC to DEB-TACE, and AEF could be a useful predictor in future studies on embolization treatment for HCC.
Article
Radiology, Nuclear Medicine & Medical Imaging
Kaicai Liu, Xiaomin Zheng, Dong Lu, Yulin Tan, Changlong Hou, Jiaying Dai, Wanyin Shi, Bo Jiang, Yibin Yao, Yuhe Lu, Qisheng Cao, Ruiwen Chen, Wangao Zhang, Jun Xie, Lei Chen, Mouying Jiang, Zhang Zhang, Lu Liu, Jie Liu, Jianying Li, Weifu Lv, Xingwang Wu
Summary: This study explored the application of a Radiological-Clinical model in predicting the prognosis of unresectable HCC patients treated with DEB-TACE, which can optimize targeted sequential therapy and thus has significant clinical value.
Review
Gastroenterology & Hepatology
Cody R. Criss, Mina S. Makary
Summary: Hepatocellular carcinoma is the second leading cause of cancer-related death globally. Despite screening efforts and treatment algorithms, recurrence rates for the disease remain high. Unlike first-line treatment, there is no consensus or general recommendations for recurrent HCC. This review examines recent evidence on salvage loco-regional therapies for recurrent HCC after failed curative-intent.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Zhongxing Shi, Dongqing Wang, Tanrong Kang, Ru Yi, Liming Cui, Huijie Jiang
Summary: This study aimed to compare the outcomes of DEB-TACE with CalliSpheres microspheres and cTACE in the treatment of unresectable HCC. The results showed that DEB-TACE group had better treatment response and survival benefits than cTACE group, despite the occurrence of some side effects in the DEB-TACE group.
RADIOLOGY AND ONCOLOGY
(2023)
Article
Oncology
Haohao Lu, Chuansheng Zheng, Bin Xiong, Xiangwen Xia
Summary: This study aimed to investigate the need for combining transcatheter arterial chemoembolization (TACE) with antiviral therapy in HBV-related hepatocellular carcinoma (HCC) patients. The results showed that TACE combined with entecavir and TACE combined with tenofovir had higher efficacy and safety, but tenofovir had some impact on renal function.
Article
Medicine, General & Internal
Ningjie Li, Jiao Chen
Summary: DEB-TACE plus apatinib achieves prolonged progression-free survival (PFS) and overall survival (OS) in huge HCC patients, while exhibiting similar adverse events occurrence compared to DEB-TACE alone.
IRISH JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Medicine, General & Internal
Marcello Andrea Tipaldi, Edoardo Ronconi, Elena Lucertini, Miltiadis Krokidis, Marta Zerunian, Tiziano Polidori, Paola Begini, Massimo Marignani, Federica Mazzuca, Damiano Caruso, Michele Rossi, Andrea Laghi
Summary: The study investigated the prognostic value of CT-based radiomics features in patients with HCC undergoing DEB-TACE, showing significant correlations with treatment response and survival outcomes. Predictive models based on texture analysis and clinical data were able to identify patients with high or low probabilities of treatment response and survival, providing valuable insights for personalized treatment approaches.
Article
Chemistry, Multidisciplinary
Omar S. Sakr, Mohamed M. A. Zaitoun, Mohamed S. Amer, Mahmoud Qubisi, Ahmed H. Elshafeey, Olivier Jordan, Gerrit Borchard
Summary: This paper introduces a new treatment modality for hepatocellular carcinoma, using highly charged, drug loaded liposomes attached to beads, allowing for localized sustained delivery of hydrophilic drugs. In an animal study, it was found that this treatment method had a slower drug release pattern, lower drug concentration, and less impact on systemic circulation.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Gastroenterology & Hepatology
Mina S. Makary, Stuart Ramsell, Eric Miller, Eliza W. Beal, Joshua D. Dowell
Summary: Hepatocellular carcinoma is the most common primary cancer of the liver with a low survival rate. Liver-directed locoregional therapies offer effective treatment options for patients with unresectable disease, with different goals based on disease stage. The review explores various therapies and prognostic factors for HCC.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Oncology
J. J. X. Lee, D. W-M Tai, S. P. Choo
Summary: With more treatment options available for advanced hepatocellular carcinoma (HCC), it is important to re-examine the timing and sequencing of locoregional and systemic therapy, especially for patients with intermediate HCC, in order to optimize responses while preserving liver reserves and achieving the best possible survival outcomes.
Article
Oncology
Fei Cao, Yi Yang, Tongguo Si, Jun Luo, Hui Zeng, Zhewei Zhang, Duiping Feng, Yi Chen, Jiaping Zheng
Summary: TACE combined with lenvatinib plus sintilimab is an effective and safe therapeutic regimen for unresectable hepatocellular carcinoma, showing high objective response rate, duration of response, progression-free survival, and overall survival.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Gastroenterology & Hepatology
Xia Bi, Adam Deising, Catherine Frenette
Editorial Material
Gastroenterology & Hepatology
Richard J. Bower, Catherine Frenette
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2020)
Article
Gastroenterology & Hepatology
Allison J. Kwong, Deepika Devuni, Connie Wang, Justin Boike, Jennifer Jo, Lisa VanWagner, Marina Serper, Lauren Jones, Rajani Sharma, Elizabeth C. Verna, Julia Shor, Margarita N. German, Alexander Hristov, Alexander Lee, Erin Spengler, Ayman A. Koteish, Gurbir Sehmbey, Anil Seetharam, Nimy John, Yuval Patel, Matthew R. Kappus, Thomas Couri, Sonali Paul, Reena J. Salgia, Quan Nhu, Catherine T. Frenette, Jennifer C. Lai, Aparna Goel
LIVER TRANSPLANTATION
(2020)
Article
Gastroenterology & Hepatology
Nicole J. Kim, Karine Rozenberg-Ben-Dror, David A. Jacob, Nicole E. Rich, Amit G. Singal, Elizabeth S. Aby, Ju Dong Yang, Veronica Nguyen, Anjana Pillai, Michael Fuchs, Andrew M. Moon, Hersh Shroff, Parul D. Agarwal, Ponni Perumalswami, Shaun Chandna, Kali Zhou, Yuval A. Patel, Nyan L. Latt, Robert Wong, Andres Duarte-Rojo, Christina C. Lindenmeyer, Catherine Frenette, Jin Ge, Neil Mehta, Francis Yao, Jihane N. Benhammou, Patricia P. Bloom, Michael Leise, Hyun-seok Kim, Cynthia Levy, Abbey Barnard, Mandana Khalili, George N. Ioannou
Summary: The survey found that the majority of providers support semi-annual HCC surveillance, with a preference for ultrasound combined with alpha fetoprotein testing. Barriers to surveillance include limited treatment options, screening test effectiveness, transportation access, and high costs.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Catherine Frenette, Zeid Kayali, Edward Mena, Parvez S. Mantry, Kathryn J. Lucas, Guy Neff, Miguel Rodriguez, Paul J. Thuluvath, Ethan Weinberg, Bal R. Bhandari, James Robinson, Nicole Wedick, Jean L. Chan, David T. Hagerty, Kris Kowdley
Summary: Emricasan was found to be safe but ineffective in treating decompensated NASH cirrhosis in a double-blind, placebo-controlled study with 217 participants. This study may provide guidance for future clinical trials in patients with decompensated cirrhosis related to non-alcoholic steatohepatitis.
JOURNAL OF HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ethan M. Weinberg, Michael P. Curry, Catherine T. Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary D. Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial, K. Rajender Reddy
Summary: The study found that Emricasan can reduce or prevent the progression of hepatic fibrosis in HCV liver transplant recipients, especially showing significant improvement in fibrosis stability and improvement in the F3 to F5 subgroup.
LIVER TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Jin Ge, Jennifer C. Lai, Justin Richard Boike, Margarita German, Nathaniel Jest, Giuseppe Morelli, Erin Spengler, Adnan Said, Alexander Lee, Alexander Hristov, Archita P. Desai, Shilpa Junna, Bhupesh Pokhrel, Thomas Couri, Sonali Paul, Catherine Frenette, Nathaniel Christian-Miller, Marcela Laurito, Elizabeth C. Verna, Usman Rahim, Aparna Goel, Arighno Das, Stewart Pine, Dyanna Gregory, Lisa B. VanWagner, Kanti Pallav Kolli
Summary: In this study, it was found that patients with nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus undergoing transjugular intrahepatic portosystemic shunt (TIPS) evaluation may be more prone to post-TIPS renal dysfunction, emphasizing the need for additional attention to cardiac and renal comorbidities before proceeding with the procedure.
LIVER TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Justin Richard Boike, Nikhilesh Ray Mazumder, Kanti Pallav Kolli, Jin Ge, Margarita German, Nathaniel Jest, Giuseppe Morelli, Erin Spengler, Adnan Said, Jennifer C. Lai, Archita P. Desai, Thomas Couri, Sonali Paul, Catherine Frenette, Elizabeth C. Verna, Usman Rahim, Aparna Goel, Dyanna Gregory, Bartley Thornburg, Lisa B. VanWagner
Summary: This study analyzed the risk factors for post-TIPS mortality and liver transplantation, finding that the relationship with MELD-Na varies depending on the indication for TIPS.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Gastroenterology & Hepatology
Catherine T. Frenette, Cynthia Levy, Sammy Saab
Summary: Cirrhosis is a serious illness with complications like hepatic encephalopathy (HE) leading to poor outcomes such as hospital readmission, decreased quality of life, and increased mortality. Guidelines recommend lactulose as first-line therapy for HE and a combination of lactulose and rifaximin to reduce the risk of HE recurrence. Approaches to improve management and prevention of HE, including adjusting medication dosages correctly and incorporating supportive care initiatives, can improve post-discharge outcomes.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Neil Mehta, Catherine Frenette, Parissa Tabrizian, Maarouf Hoteit, Jennifer Guy, Neehar Parikh, T. Tara Ghaziani, Renu Dhanasekaran, Jennifer L. Dodge, Brahma Natarajan, Matthew L. Holzner, Leana Frankul, Wesley Chan, Austin Fobar, Sander Florman, Francis Y. Yao
Summary: This study is the first multiregional study based on UNOS-DS criteria, showing a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. Despite a 2-year post-LT survival rate of 95%, a high rate of tumor understaging was observed.
Article
Oncology
Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron, Stephen L. Chan, Jean Frederic Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
Summary: Better baseline liver function, as measured by ALBI grade or CPS, may be associated with better survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) undergoing treatment with lenvatinib or sorafenib.
Review
Gastroenterology & Hepatology
Leana Frankul, Catherine Frenette
Summary: Downstaging treatment is crucial for patients with unresectable hepatocellular carcinoma who are not eligible for liver transplantation, but severe organ shortage limits its broader application. Debate over the optimal treatment protocol and assessment method for downstaging treatment is pushing the boundaries of liver transplantation candidate selection.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
David J. Hermel, Emma Z. Du, Ray Lin, Catherine T. Frenette, Darren S. Sigal
Summary: LEL-HCC is a rare liver tumor with potential efficacy and safety of immune checkpoint blockade, although current evidence-based practices are lacking. A case report demonstrates successful treatment of LEL-HCC with an immune checkpoint inhibitor. More robust, large-scale analysis is needed for better evaluation of treatment strategies and outcomes for this rare tumor subtype.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Sarah A. Rojas, Job G. Godino, Adam Northrup, Maureen Khasira, Aaron Tam, Lisa Asmus, Catherine Frenette, Christian B. Ramers
Summary: The study found that in urban FQHC clinics serving a low-income majority homeless population, HCV treatment administered by nonspecialist providers was as effective as treatment provided by a specialist.
HEPATOLOGY COMMUNICATIONS
(2021)
Article
Endocrinology & Metabolism
Ali Y. Fakhreddine, Samantha Bagsic, Ken Fujioka, Catherine T. Frenette
Summary: This study retrospectively reviewed the use of pharmacologic weight loss treatment in patients with advanced liver disease, finding a significant mean weight loss following prescription of weight-loss medications. However, no significant effects were observed on MELD score or hospitalization rates. While preliminary safety and efficacy outcomes suggest feasibility, further prospective studies are needed to evaluate potential treatment gaps in obesity management in this vulnerable population.
OBESITY SCIENCE & PRACTICE
(2021)